Academic Journal
CD81 is a novel immunotherapeutic target for B cell lymphoma
| العنوان: | CD81 is a novel immunotherapeutic target for B cell lymphoma |
|---|---|
| المؤلفون: | Vences-Catalán, Felipe, Kuo, Chiung-Chi, Rajapaksa, Ranjani, Duault, Caroline, Andor, Noemi, Czerwinski, Debra K., Levy, Ronald, Levy, Shoshana |
| المساهمون: | Stanford Cancer Institute, Stanford, Department of Defense, American Society of Immunology, National Institutes of Health |
| المصدر: | Journal of Experimental Medicine ; volume 216, issue 7, page 1497-1508 ; ISSN 0022-1007 1540-9538 |
| بيانات النشر: | Rockefeller University Press |
| سنة النشر: | 2019 |
| الوصف: | The tetraspanin CD81 was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target CD81, has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1084/jem.20190186 |
| الاتاحة: | http://dx.doi.org/10.1084/jem.20190186 https://rupress.org/jem/article-pdf/216/7/1497/1762577/jem_20190186.pdf |
| Rights: | http://www.rupress.org/terms/ ; http://creativecommons.org/licenses/by-nc-sa/4.0/ |
| رقم الانضمام: | edsbas.D4095254 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1084/jem.20190186 |
|---|